BIIBNASDAQ
Biogen Inc.
$0.00
0.000.00%
15-min delay
E
Open—
Prev Close—
Market Cap$36.89B
P/E (TTM)106.88
EPS$15.28
Earnings2027-02-17
DAY RANGE
$0.00$0.00

Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich's Ataxia; QALSODY for amyotrophic lateral sclerosis; FUMADERM for plaque psoriasis; BENEPALI, an etanercept biosimilar; and IMRALDI, an adalimumab biosimilar. Biogen Inc. focuses on addressing unmet medical needs in the fields of neurology, including multiple sclerosis, spinal muscular atrophy, and rare diseases like Friedreich's Ataxia and ALS. Its portfolio emphasizes innovative treatments that target the underlying mechanisms of these debilitating conditions, serving patients through specialized healthcare channels worldwide. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a vital role in advancing biopharmaceutical solutions for complex neurological disorders.

SectorHealth Technology
Employees7500
ISINUS09062X1037
Address225 Binney Street, Cambridge, MA, 02142
Key Statistics
Full Stats
Market Cap$36.89B
Enterprise Value$43.40B
P/E Ratio (TTM)106.88
P/S Ratio3.69
P/B Ratio1.95
Forward P/E99.14
EPS (TTM)$2.34
EPS (FY)$15.28
Revenue (TTM)$9.90B
Profit Margin3.51%
Operating Margin17.31%
ROE7.39%
Debt/Equity0.41
Avg Vol (30d)1.2M
Beta (1Y)0.06
Beta (3Y)0.19
Beta (5Y)0.10
Shares Out147.82M
Float146.70M
Dividend—
Next Earnings2027-02-17
Short Interest—
52-Week Range
$0.00
$160.36$261.00

Upgrades & Downgrades

Members

Every rating change, who made it, and what it moved from.

Sign in to viewCreate a free account

Free account. No card required.

Grades Consensus

Members

Analyst price targets — high, low, median and where it sits now.

Sign in to viewCreate a free account

Free account. No card required.

Price Target Consensus

Members

Analyst price targets — high, low, median and the upside from here.

Sign in to viewCreate a free account

Free account. No card required.

Ratings Snapshot

Members

DCF, Piotroski, Altman Z and returns scores, in one grade.

Sign in to viewCreate a free account

Free account. No card required.

Forward Estimates

Members

Quarterly revenue and EPS estimates, with the history of beats.

Sign in to viewCreate a free account

Free account. No card required.

Seasonality

Members

How this ticker has traded month by month over the last decade.

Sign in to viewCreate a free account

Free account. No card required.